| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | -0.082 | 0.1 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.075 | 0.1 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |